Lilly launches Employer Connect to widen workplace obesity coverage

Eli Lilly and Company announced on March 5, 2026, the launch of Employer Connect, a platform meant to help employers offer coverage for obesity medications to their workers ^[1]. The program brings together more than fifteen independent program administrators that design benefit plans ranging from basic cost-sharing to full obesity-care support, including coaching and clinical services ^[1].

The company says the effort targets a real coverage problem. Obesity affects more than 100 million American adults and costs the U.S. economy over $1.7 trillion a year, including $480 billion in direct medical costs and $1.24 trillion in lost productivity, according to figures Lilly cited ^[1]. Despite this, roughly half of employees with commercial insurance have no coverage for obesity medications through their employer-sponsored plans ^[1].

Through the new platform, Lilly's Zepbound (tirzepatide) KwikPen is being made available to network pharmacies at a discounted price of $449 across all approved doses ^[1]. Actual costs to employers will depend on which pharmacy and program administrator they choose, and what employees pay out of pocket will vary based on each employer's cost-sharing design and the fees set by administrators ^[1]. The medication is dispensed through a network that includes pharmacies HealthDyne and CenterWell ^[1].

Participating administrators already on the platform include 9amHealth, Andel, Calibrate Health, Crux Health, eMed, FlyteHealth, Form Health, Goodpath, GoodRx, Ilant Health, Mark Cuban Cost Plus Drug Company, Onsera Health, ReviveHealth, SALTA Direct Primary Care, Sesame, Teladoc Health, Transcarent and Waltz Health, and Lilly says it plans to add more ^[1]. "For far too many people living with obesity, starting or staying on treatment isn't just a medical decision, it's an access decision driven by coverage and cost," said Ilya Yuffa, an executive vice president at Lilly ^[1]. Kevin Hern, senior vice president of Lilly Employer, said the goal is to let employers offer coverage "outside traditional benefit designs" while preserving choice for both patients and providers ^[1].

Why it matters for patients

For people whose employer plans don't currently cover obesity drugs, this program could open a path to lower-cost access to Zepbound, though the actual price an employee pays will depend entirely on which administrator and cost-sharing model their employer selects ^[1]. Lilly notes that Zepbound was the most prescribed weight-management medication in the U.S. in 2025, and the FDA recently approved a single-patient-use KwikPen version that delivers four weekly injections from one device ^[1].

Clinical trial data cited by Lilly show that in the 72-week SURMOUNT-1 trial, adults taking the 15 mg dose of Zepbound lost an average of 20.9% of body weight, compared with 3.1% for those on placebo ^[1]. In the open-label SURMOUNT-5 study, which compared Zepbound directly with injectable Wegovy (semaglutide), participants on Zepbound's maximum tolerated dose lost an average of 20.2% of body weight (50 pounds), versus 13.7% (33 pounds) for those on Wegovy's maximum tolerated dose; Lilly notes this was a less rigorous, open-label design, so the findings are less certain than a blinded trial ^[1]. Zepbound carries warnings about thyroid tumors, severe stomach problems, dehydration, gallbladder issues, pancreatitis, allergic reactions, low blood sugar when combined with certain other medicines, and mood changes, according to the prescribing information included with the announcement ^[1].

What this program does not resolve is guaranteed universal coverage. Access still depends on individual employers choosing to participate and selecting a plan design, so workers at companies that don't sign on will see no change in their coverage ^[1].

What happens next

Lilly says it will continue adding program administrators to the Employer Connect platform over time ^[1]. Employers, benefits consultants, or other interested parties can contact Lilly directly to learn more about joining, but the sources do not specify a timeline for when additional administrators or broader employer adoption might occur ^[1].